CCR5 and cancer: We found that the mTOR/70S6K/4EBP14EBP1 signaling pathway was significantly activated in a dose-dependent manner in RKO cells treated with rCCL8, while inhibiting CCR5 with Maraviroc showed the opposite effect, suggesting that the mTOR/70S6K/4EBP1 signaling pathway might be involved in the pro-cancer effects of CCL8/CCR5 (Figure 6A,B).